Drug · DIN 02296810
LUCENTIS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 29, 2014; first marketed July 26, 2007.
- Drug Identification Number (DIN)
- 02296810
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravitreal
- Therapeutic class (ATC)
- Ranibizumab S01LA04
- Class
- Human
- Record last updated
- June 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RANIBIZUMAB | 10 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 28, 2014: NOC 15653Supplement to a New Drug Submission (SNDS) · New presentation
- April 30, 2008: NOC 9528New Drug Submission (NDS) · Manufacturer name change
- June 26, 2007: NOC 8866New Drug Submission (NDS)
Other DINs named LUCENTIS
- DIN 02425629 · Marketed